Panelists:
Robert Carnahan, PhD
Associate Director, Vanderbilt Vaccine Center
Professor, Pediatrics and Radiology and Radiologic Sciences
Vanderbilt University Medical Center
Lauren Williamson, PhD
Research Assistant Professor, Pediatrics
Pediatric Infectious Diseases
Vanderbilt University Medical Center
Vincent Pai
Director, Product Management
Bruker Cellular Analysis
- Time:
Even as the world continues to recover from the COVID pandemic, the threat of another global health crisis seems assured. Before that happens, it will be essential to discover and develop novel therapeutics, such as monoclonal antibodies, that effectively target emerging viral threats like hantaviruses and SARS-CoV-2.
In this GEN webinar, researchers from Vanderbilt University Medical Center describe recent advancements in therapeutic antibody discovery, enabled by the Bruker Beacon® Platform, that can support a rapid response to novel viruses. They will present methods for rapidly isolating and characterizing human monoclonal antibodies, particularly those targeting the SARS-CoV-2 spike protein. They will cover the scientific challenges of targeting diverse viral strains and the role of broad-spectrum antibodies such as AstraZeneca’s Evusheld, in addressing viral variants. The speakers will also present achievements in the pandemic preparedness platform development—an effort to develop highly potent monoclonal antibodies against current and future viral threats.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.
Produced with support from:
